Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820352 | 0.82 | CYP3A4 (0.39) | CYP3A4CYP19A1USP2RAB9ACYP1A2 | |
| SCHEMBL12197702 | 0.80 | MEN1 (0.48) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15119932 | 0.79 | CYP3A4 (0.37) | CYP3A4CYP19A1USP2RAB9ACYP1A2 | |
| SCHEMBL11681879 | 0.74 | NAAA (0.39) | CYP3A4MEN1KMT2AATM | |
| SCHEMBL20097983 | 0.74 | KIF11 (0.39) | CYP3A4CYP19A1USP2RAB9AKIF11 | |
| SCHEMBL12197886 | 0.72 | AAK1 (0.40) | CYP3A4CYP19A1USP2RAB9AKIF11 | |
| SCHEMBL13741610 | 0.71 | CYP19A1 (0.42) | CYP3A4CYP19A1USP2RAB9ACYP1A2 | |
| SCHEMBL18270401 | 0.66 | KIF11 (0.43) | CYP3A4CYP19A1USP2RAB9ACYP1A2 | |
| SCHEMBL20710610 | 0.65 | CYP19A1 (0.48) | CYP3A4CYP19A1USP2RAB9AMEN1 | |
| SCHEMBL2554687 | 0.65 | CYP19A1 (0.48) | CYP3A4CYP19A1USP2RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9199996-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9045482-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150005322-A1 | PYRIDO[3,4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8859561-B2 | Pyrido[4,3-b]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184304-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005322-A1 | PYRIDO[3,4-B] INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | CYP3A4 568/4885CYP19A1 3838/4885USP2 3305/4885 |
| US-20130184304-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP3A4 574/4885CYP19A1 3876/4885USP2 3280/4885 |
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP3A4 574/4885CYP19A1 3876/4885USP2 3280/4885 |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP3A4 574/4885CYP19A1 3876/4885USP2 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.